Dr Harry Cooper discusses Pneumococcal Pneumonia

Dr Harry Cooper discusses the seriousness of pneumococcal pneumonia and how to protect oneself against pneumonia, such as having the free pneumococcal pneumonia vaccination available to Australians aged 65 and over.

Pneumococcal Pneumonia from VIVA! Communications on Vimeo.

Share

Exciting news at VIVA!

A huge congratulations to VIVA! team member Mahsa, on the exciting news of her engagement. We were thrilled to see her waltz into the VIVA! office last week with a gorgeous sparkling ring on her finger and a smile to match.

We wish Mahsa and Max all the best for their engagement and upcoming wedding plans.

Team VIVA!

Mahsa with her gorgeous ring and flowers from the VIVA! Team

 

Share
Tags:
Posted in Recent Post Team VIVA! by viva. No Comments

Dr John Skerrit appointed as new head of TGA

VIVA! Communications welcomes The Commonwealth Department of Health and Ageing’s (DoHA) appointment of Dr John Skerritt as the new National Manager of the Therapeutic Goods Administration (TGA), effective at the end of May.

Dr John Skerrit appointed as new head of TGA

The TGA is the national body responsible for regulating therapeutic goods including medicines, medical devices, blood and blood products.

According to the Secretary of the DoHA, Professor Jane Halton, Dr Skerritt will bring to the role his extensive experience in medical, agricultural and environmental policy, regulation, research, research management, technology application and commercialisation.

“Dr Skerritt currently leads more than 1200 staff (including 700 regulatory staff in two major science-based regulatory Divisions) and has more than 17 years experience managing laboratory programs and operations in diagnostics, cell culture, biomedical instrumentation, chemistry and biochemistry,” Professor Halton said.

Share

Originator manufacturers bracing for further PBS price cuts

The ongoing price disclosure system brokered by Medicines Australia and the Government will see another 13 medicines attract significant price cuts ranging from 11 to 77 per cent from August 1 this year.

The medication price cuts are in addition to the broadbrush $1.9 billion in PBS savings that constitute the Memorandum of Understanding (MoU) between Medicines Australia (MA) and the Government, which saw 74 medicines slashed in price last month.

Manufacturers of originators (brand name medicines) are bracing themselves for future price cuts as patents expire and medications become subject to price disclosure.

The 13 medicines, representing more than 200 brands include Amisulpride, Bisoprolol, Cefalotin, Doxorubicin, Escitalopram, Levetiracetam, Meloxicam, Mitozantrone, Ondansetron, Oxaliplatin, Oxybutinin, Perindopril and Prochlorperazine.

Share

VIVA! on location – Western Australia

Join VIVA! team members Kirsten Bruce & Denise Vrontas as they take you on a tour of Yke’s Bornholm residence in regional WA.

Yke is living with complex Parkinson’s & is managing his disease effectively, which allows him to enjoy a full, active lifestyle.

Check out the video below:

On location with VIVA! from VIVA! Communications on Vimeo.

To see the full story on Yke, or to learn more, contact VIVA! Communications on 02 9968 3741.

Share
Posted in Team VIVA! by viva. No Comments